SFDA Spells Out Tasks For 2009
This article was originally published in PharmAsia News
Executive Summary
China's State FDA will concentrate on improving the regulation of standards and supervision of food and drugs in 2009, with the aim of raising standards for all drugs marketed within five years. The agency will speed up its action plan by strengthening international cooperation on formulating standards; revising or raising the quality level of 2,000 drugs; and revising the 2010 Chinese Pharmacopoeia edition. In addition, SFDA will finish the revision of Regulations for the Supervision and Administration of Medical Devices; conduct research on revising the Drug Administration Law and Regulations for the Hygiene Supervision on Cosmetics; implement Provisions for Drug Registration and its complementary documents; as well as continuously formulate and standardize technical appraisal guidelines for drugs and medical devices. (Click here for more - Chinese Language)
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.